Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.

ABSTRACT:

Background

Lurbinectedin is a novel anticancer agent currently undergoing late-stage (Phase II /III) clinical evaluation in platinum-resistant ovarian, BRCA1/2-mutated breast and small-cell lung cancer. Lurbinectedin is structurally related to trabectedin and it inhibits active transcription and the DNA repair machinery in tumour cells.

Methods

In this study we investigated whether lurbinectedin has the ability to modulate the inflammatory microenvironment and the viability of myeloid cells in tumour-bearing mice.

Results

Administration of lurbinectedin significantly and selectively decreased the number of circulating monocytes and, in tumour tissues, that of macrophages and vessels. Similar findings were observed when a lurbinectedin-resistant tumour variant was used

SUBMITTER: Belgiovine C 

PROVIDER: S-EPMC5572168 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature